<?xml version="1.0" encoding="UTF-8"?>
<p>Although 
 <italic>M. mycetomatis</italic> is by far the most common causative agent for mycetoma and has more strains tested than the other species, no epidemiologic cut-off values or clinical breakpoints have been set for this or any of the other common causative agents, neither by the CLSI or the EUCAST. Therefore there is currently no correlation between the MIC or clinical failure or success. The CLSI developed clinical breakpoints only for 
 <italic>Candida</italic>, while the EUCAST defined different method-based clinical breakpoints for both 
 <italic>Candida</italic> and 
 <italic>Aspergillus</italic>.
 <xref rid="bib7" ref-type="bibr">
  <sup>7</sup>
 </xref> For itraconazole, clinical breakpoints as determined by the EUCAST are 0.06 µg/ml for 
 <italic>Candida albicans</italic> and 
 <italic>Candida dubliniensis</italic>, 0.125 µg/ml for 
 <italic>Candida parapsilosis</italic> and 
 <italic>Candida tropicalis</italic> and 1 µg/ml for 
 <italic>Aspergillus flavus</italic>, 
 <italic>Aspergillus fumigatus</italic>, 
 <italic>Aspergillus nidulans</italic> and 
 <italic>Aspergillus terreus</italic>.
 <xref rid="bib67" ref-type="bibr">
  <sup>67</sup>
 </xref> For posaconazole, the clinical breakpoints are 0.06 µg/ml for 
 <italic>C. albicans</italic>, 
 <italic>C. dubliniensis</italic>, 
 <italic>C. parapsilosis</italic> and 
 <italic>C. tropicalis</italic> and 0.125 µg/ml for 
 <italic>A. fumigatus</italic> and 
 <italic>A. terreus</italic>.
 <xref rid="bib67" ref-type="bibr">
  <sup>67</sup>
 </xref> The MIC50s obtained for most causative agents of mycetoma are below the clinical breakpoints for the filamentous aspergilli.
</p>
